86405 20210310171108.0 doi 10.1177/1756284819847034 sideral 115097 ART-2019-115097 eng Chaparro, M. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain 2019 Access copy available to the general public Unrestricted Background: Inflammatory bowel disease (IBD) is associated with a considerable burden to the patient and society. However, current data on IBD incidence and burden are limited because of the paucity of nationwide epidemiological studies, heterogeneous designs, and a low number of participating centers and sample size. The EpidemIBD study is a large-scale investigation to provide an accurate assessment of the incidence of IBD in Spain, as well as treatment patterns and outcomes. Methods: This multicenter, population-based incidence cohort study included patients aged >18 years with IBD (Crohn’s disease, ulcerative colitis, or unclassified IBD) diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population. Each participating patient will attend 10 clinic visits during 5 years of follow up. Demographic data, IBD characteristics and family history, complications, treatments, surgeries, and hospital admissions will be recorded. Results: The EpidemIBD study is the first large-scale nationwide study to investigate the incidence of IBD in Spain. Enrollment is now completed and 3627 patients are currently being followed up. Conclusions: The study has been designed to overcome many of the limitations of previous European studies into IBD incidence by prospectively recruiting a large number of patients from all regions of Spain. In addition to epidemiological information about the burden of IBD, the 5-year follow-up period will also provide information on treatment patterns, and the natural history and financial burden of IBD. info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI16-01296 info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI17-00143 info:eu-repo/semantics/openAccess by-nc http://creativecommons.org/licenses/by-nc/3.0/es/ 3.52 2019 GASTROENTEROLOGY & HEPATOLOGY 40 / 88 = 0.455 2019 Q2 T2 1.29 2019 Gastroenterology 2019 Q1 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Barreiro-de Acosta, M. Benítez, J.M. Cabriada, J.L. Casanova, M.J. Ceballos, D. Esteve, M. Fernández, H. Ginard, D. (orcid)0000-0003-0076-3529 Gomollón, F. Universidad de Zaragoza Lorente, R. Nos, P. Riestra, S. Rivero, M. Robledo, P. Rodríguez, C. Sicilia, B. Torrella, E. Garre, A. García-Esquinas, E. Rodríguez-Artalejo, F. Gisbert, J.P. Alfambra, E. 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 12 (2019), 1-11 Therap. adv. in gastroenterol. Therapeutic Advances in Gastroenterology 1753-283X 2088779 http://zaguan.unizar.es/record/86405/files/texto_completo.pdf Versión publicada 122939 http://zaguan.unizar.es/record/86405/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:86405 articulos driver 2021-03-10-17:01:26 ARTICLE